FYARRO
Total Payments
$23.1M
Transactions
1,672
Doctors
107
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5.6M | 1,116 | 2 |
| 2023 | $17.2M | 301 | 1 |
| 2022 | $206,815 | 255 | 105 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $22.9M | 1,417 | 99.1% |
| Honoraria | $146,655 | 72 | 0.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28,705 | 10 | 0.1% |
| Travel and Lodging | $10,349 | 29 | 0.0% |
| Food and Beverage | $8,356 | 136 | 0.0% |
| Consulting Fee | $6,750 | 6 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $6,000 | 2 | 0.0% |
Payments by Type
Research
$22.9M
1,417 transactions
General
$206,815
255 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/_TSC2 Genes (PRECISION 1) | Aadi Bioscience, Inc. | $14.9M | 0 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | Aadi Bioscience, Inc. | $3.7M | 2 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. | Aadi Bioscience, Inc. | $2.3M | 1 |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | Aadi Bioscience, Inc. | $761,944 | 0 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | Aadi Bioscience, Inc. | $494,611 | 0 |
| Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | Aadi Bioscience, Inc. | $400,682 | 0 |
| Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas | Aadi Bioscience, Inc. | $165,392 | 0 |
| A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | Aadi Bioscience, Inc. | $113,598 | 0 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1TSC2 Genes PRECISION 1 | Aadi Bioscience, Inc. | $60,202 | 0 |
Top Doctors Receiving Payments for FYARRO — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Michael Wagner | Medical Oncology | Seattle, WA | $1,550 | 2 |
| Michael Lattanzi | Medical Oncology | Austin, TX | $1,500 | 1 |
| , M.D | Medical Oncology | Boston, MA | $1,500 | 1 |
| , M.D | Urology | Phoenix, AZ | $1,500 | 1 |
| , MD | Internal Medicine | Detroit, MI | $1,500 | 1 |
| , M.D | Hematology & Oncology | New Haven, CT | $1,500 | 1 |
| , MD | Medical Oncology | Ann Arbor, MI | $1,500 | 1 |
| , M.D | Internal Medicine | Duarte, CA | $1,500 | 1 |
| , M.D | Medical Oncology | Baltimore, MD | $1,500 | 1 |
| , M.D./PH.D | Internal Medicine | Scottsdale, AZ | $1,500 | 1 |
| , MS | Hematology & Oncology | San Francisco, CA | $1,500 | 1 |
| Evan Yu | Medical Oncology | Seattle, WA | $1,500 | 1 |
| , MD | Medical Oncology | Houston, TX | $1,300 | 1 |
| , M.D., PH. D | Medical Oncology | Miami, FL | $1,268 | 2 |
| , M.D | Hematology | Tyler, TX | $1,000 | 1 |
| , M.D | Medical Oncology | Seattle, WA | $1,000 | 1 |
| , MD | Medical Oncology | Tyler, TX | $1,000 | 1 |
| , M.D | Hematology & Oncology | San Antonio, TX | $1,000 | 1 |
| , MD, FACP | Hematology & Oncology | Phoenix, AZ | $1,000 | 1 |
| , MD | Hematology & Oncology | Denver, CO | $1,000 | 1 |
| , M.D | Urology | Durham, NC | $1,000 | 1 |
| , MD | Internal Medicine | Portland, OR | $924.76 | 2 |
| , MD | Internal Medicine | San Francisco, CA | $500.00 | 1 |
| , MD | Medical Oncology | Portland, OR | $500.00 | 1 |
| , CRNP | Adult Health | Philadelphia, PA | $289.76 | 2 |
Ad
Manufacturing Companies
- Aadi Bioscience, Inc. $23.1M
Product Information
- Type Drug
- Total Payments $23.1M
- Total Doctors 107
- Transactions 1,672
About FYARRO
FYARRO is a drug associated with $23.1M in payments to 107 healthcare providers, recorded across 1,672 transactions in the CMS Open Payments database. The primary manufacturer is Aadi Bioscience, Inc..
Payment data is available from 2022 to 2024. In 2024, $5.6M was paid across 1,116 transactions to 2 doctors.
The most common payment nature for FYARRO is "Unspecified" ($22.9M, 99.1% of total).
FYARRO is associated with 9 research studies, including "Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/_TSC2 Genes (PRECISION 1)" ($14.9M).